Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis
ObjectiveThe primary objective of this study was to examine the levels of serum EZH2 in patients diagnosed with bladder cancer, and subsequently evaluate its potential as a biomarker for both the diagnosis and prognosis of bladder cancer.MethodsBlood samples were obtained from 115 bladder cancer pat...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1303918/full |
| _version_ | 1797294293844492288 |
|---|---|
| author | Feng Li Pengqiao Wang Jun Ye Guoping Xie Jinfeng Yang Wei Liu |
| author_facet | Feng Li Pengqiao Wang Jun Ye Guoping Xie Jinfeng Yang Wei Liu |
| author_sort | Feng Li |
| collection | DOAJ |
| description | ObjectiveThe primary objective of this study was to examine the levels of serum EZH2 in patients diagnosed with bladder cancer, and subsequently evaluate its potential as a biomarker for both the diagnosis and prognosis of bladder cancer.MethodsBlood samples were obtained from 115 bladder cancer patients and 115 healthy persons. We measured the EZH2 concentrations in the serum of these subjects via enzyme-linked immunosorbent assay (ELISA). To assess the diagnostic performance of serum EZH2 in detecting bladder cancer, we plotted receiver operating characteristic (ROC) curves and calculated their corresponding area under the curve (AUC). We also used the Cox regression model and log-rank test to investigate the correlation between EZH2 levels and clinicopathological characteristics, and survival rates of bladder cancer patients.ResultsSerum EZH2 levels were significantly higher in bladder cancer patients when compared to those in healthy persons. Serum EZH2 levels exhibited a significant correlation with TNM stage, lymph node metastasis, muscle invasion, and tumor size. At a cutoff value of 8.23 ng/mL, EZH2 was able to differentiate bladder cancer patients from healthy persons, with an AUC of 0.87, a sensitivity of 81.31%, and a specificity of 78.42%. High EZH2 levels correlated with poor overall survival rates and progression-free survival rates of bladder cancer patients.ConclusionsSerum EZH2 levels were elevated in bladder cancer patients, and patients with higher serum EZH2 levels exhibited a poorer prognosis. This indicates that serum EZH2 could be a novel biomarker for bladder cancer diagnosis and prognosis. Such findings could improve the prognosis of bladder cancer patients by facilitating early detection and continuous monitoring. |
| first_indexed | 2024-03-07T21:28:09Z |
| format | Article |
| id | doaj.art-d0375847389d4786a45b2a405412c86b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-03-07T21:28:09Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-d0375847389d4786a45b2a405412c86b2024-02-27T04:23:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2024-02-011410.3389/fonc.2024.13039181303918Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosisFeng Li0Pengqiao Wang1Jun Ye2Guoping Xie3Jinfeng Yang4Wei Liu5Department of Urology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Medical Administration, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Clinical Laboratory, The Second Affiliated Hospital of Guizhou Medical University, Kaili, ChinaDepartment of Urology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Gastrointestinal Surgery, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaDepartment of Oncology, The First Affiliated Hospital of Chengdu Medical College, Chengdu, ChinaObjectiveThe primary objective of this study was to examine the levels of serum EZH2 in patients diagnosed with bladder cancer, and subsequently evaluate its potential as a biomarker for both the diagnosis and prognosis of bladder cancer.MethodsBlood samples were obtained from 115 bladder cancer patients and 115 healthy persons. We measured the EZH2 concentrations in the serum of these subjects via enzyme-linked immunosorbent assay (ELISA). To assess the diagnostic performance of serum EZH2 in detecting bladder cancer, we plotted receiver operating characteristic (ROC) curves and calculated their corresponding area under the curve (AUC). We also used the Cox regression model and log-rank test to investigate the correlation between EZH2 levels and clinicopathological characteristics, and survival rates of bladder cancer patients.ResultsSerum EZH2 levels were significantly higher in bladder cancer patients when compared to those in healthy persons. Serum EZH2 levels exhibited a significant correlation with TNM stage, lymph node metastasis, muscle invasion, and tumor size. At a cutoff value of 8.23 ng/mL, EZH2 was able to differentiate bladder cancer patients from healthy persons, with an AUC of 0.87, a sensitivity of 81.31%, and a specificity of 78.42%. High EZH2 levels correlated with poor overall survival rates and progression-free survival rates of bladder cancer patients.ConclusionsSerum EZH2 levels were elevated in bladder cancer patients, and patients with higher serum EZH2 levels exhibited a poorer prognosis. This indicates that serum EZH2 could be a novel biomarker for bladder cancer diagnosis and prognosis. Such findings could improve the prognosis of bladder cancer patients by facilitating early detection and continuous monitoring.https://www.frontiersin.org/articles/10.3389/fonc.2024.1303918/fullEZH2biomarkerbladder cancerdiagnosisoverall survival rateprogression-free survival rate |
| spellingShingle | Feng Li Pengqiao Wang Jun Ye Guoping Xie Jinfeng Yang Wei Liu Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis Frontiers in Oncology EZH2 biomarker bladder cancer diagnosis overall survival rate progression-free survival rate |
| title | Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| title_full | Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| title_fullStr | Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| title_full_unstemmed | Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| title_short | Serum EZH2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| title_sort | serum ezh2 is a novel biomarker for bladder cancer diagnosis and prognosis |
| topic | EZH2 biomarker bladder cancer diagnosis overall survival rate progression-free survival rate |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1303918/full |
| work_keys_str_mv | AT fengli serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis AT pengqiaowang serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis AT junye serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis AT guopingxie serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis AT jinfengyang serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis AT weiliu serumezh2isanovelbiomarkerforbladdercancerdiagnosisandprognosis |